NKTX Stock Price
Nkarta, Inc.
NKTX stock price is $2.03 (-3.33% on the day), giving Nkarta, Inc. a market cap of $145.40M. Below are the price chart, the MarketXLS Rank, the company profile and the latest news.
NKTX Stock Overview
- Price
- $2.03
- Previous close
- $2.10
- Open
- $2.08
- Market cap
- $145.40M
- P/E ratio
- -1.4
- 52-week range
- $1.70 - $3.72
- 1-year price target
- $10.83
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NGS
- MarketXLS Rank
- 31
About Nkarta, Inc.
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | NKTX | $2.03 | -3.3% | 702.28K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |